Posted by Michael Wonder on 14 Mar 2024
Cybin receives FDA breakthrough therapy designation for its novel psychedelic molecule CYB003
13 March 2024 - First known breakthrough therapy designation granted by the FDA for an adjunctive psychedelic based therapy for the treatment of major depressive disorder.
Cybin today announced that the FDA has granted BTD to CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of major depressive disorder.
